| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| Efectos de un Antagonista/Agonista Inverso Del Receptor CB1 (Rimonabant) Sobre la Capacidad Para la deambulación en Lesionados Medulares Incompletos [NCT05622994] | Phase 2 | 80 participants (Anticipated) | Interventional | 2022-11-30 | Not yet recruiting |
| A Randomized, Double Blind, Two-arm Placebo Controlled, 12-Month Study of the Effects of Rimonabant 20mg Once Daily on the Amount and the Activity of Visceral Fat in Abdominally Obese Patients With Metabolic Syndrome. [NCT00299325] | Phase 3 | 254 participants (Actual) | Interventional | 2006-02-28 | Completed |
| A Double-blind, Randomized, Placebo-controlled, Parallel Group Study of Rimonabant 20 mg Daily for the Treatment of Type 2 Diabetic Patients With Nonalcoholic Steatohepatitis (NASH). [NCT00577148] | Phase 3 | 89 participants (Actual) | Interventional | 2008-02-29 | Terminated(stopped due to Company decision taken in light of demands by certain national health authorities) |
| Randomized, Multinational, Multicenter, Double-blind, Placebo-controlled, Two-arm Parallel Group Trial of Rimonabant 20 mg OD for Reducing the Risk of Major Cardiovascular Events in Abdominally Obese Patients With Clustering Risk Factors [NCT00263042] | Phase 3 | 18,695 participants (Actual) | Interventional | 2005-12-31 | Terminated(stopped due to Company decision taken in light of demands by certain national health authorities) |
| Randomized, Multicenter, Double-blind, Placebo-controlled, Two-arm Parallel Group Trial of Rimonabant 20-mg od, for Inhibition of Atherosclerosis Progression Assessed by Carotid Artery Intima-media Thickness (CIMT), in Overweight Patients With Additional [NCT00228176] | Phase 3 | 661 participants (Actual) | Interventional | 2005-08-31 | Terminated(stopped due to Company decision taken in light of demands by certain national health authorities) |
| A Randomized, Double Blind, Placebo Controlled Study Evaluating the Glycemic Effect of Rimonabant Added to Metformin in Patients With Type 2 Diabetes Insufficiently Controlled With Metformin Monotherapy [NCT00690456] | Phase 3 | 403 participants (Actual) | Interventional | 2008-05-31 | Terminated(stopped due to Company decision taken in light of demands by certain national health authorities) |
| A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess the Efficacy and Safety of Long-term Administration of Rimonabant in the Prevention of Type 2 Diabetes in Patients With Prediabetic Status (i.e., Impaired Fasting [NCT00325650] | Phase 3 | 2,420 participants (Actual) | Interventional | 2006-05-31 | Terminated(stopped due to Company decision taken in light of demands by certain national health authorities) |
| A Randomized, Double-Blind, Parallel-Group, Multicenter, Multinational Study to Assess the Long-Term Effect, Over 1 Year, of Rimonabant 10 mg in Comparison With Rimonabant 20 mg After an Initial Treatment Period of 6 Months With Rimonabant 20 mg in Overwe [NCT00678483] | Phase 3 | 331 participants (Actual) | Interventional | 2008-04-30 | Terminated(stopped due to Company decision taken in light of demands by certain national health authorities) |
| A Randomized, Double-Blind, Parallel-Group, Multicenter, Multinational Study to Assess Glycemic Control With Rimonabant in Comparison With Glimepiride Over 1 Year in Overweight/Obese Type2 Diabetic Patients Not Adequately Controlled With Metformin [NCT00449605] | Phase 3 | 508 participants (Actual) | Interventional | 2007-03-31 | Terminated(stopped due to Company decision taken in light of demands by certain national health authorities) |
| A Double-blind, Randomized, Placebo-controlled, Parallel Group Study of Rimonabant 20 mg Daily for the Treatment of Non-diabetic Patients With Nonalcoholic Steatohepatitis (NASH) [NCT00576667] | Phase 3 | 165 participants (Actual) | Interventional | 2008-01-31 | Terminated(stopped due to Company decision taken in light of demands by certain national health authorities) |
| A European Randomized, Parallel Group, Two-arm Placebo-controlled, Double-blind Multicenter Study of Rimonabant 20mg Once Daily in the Treatment of Abdominally Obese Patients With Dyslipidemia With or Without Other Comorbidities [NCT00412698] | Phase 3 | 645 participants (Actual) | Interventional | 2006-12-31 | Terminated(stopped due to Company decision has been taken in light of recent demands by certain national health authorities) |
| Early Detection of Atherosclerosis in the Primary Care Setting: a Randomized Trial to Assess the Efficacy of a Novel Strategy in the Primary Prevention of Cardiovascular Diseases. [NCT00734123] | Phase 4 | 2,948 participants (Anticipated) | Interventional | 2008-04-30 | Recruiting |
| The Effects of the Cannabinoid-1 Receptor Antagonist, Rimonabant, on Weight and Metabolic Risk Factors in People With Schizophrenia [NCT00547118] | Phase 2 | 17 participants (Actual) | Interventional | 2007-11-30 | Terminated(stopped due to Withdrawn due to medication withdrawal from the EMEA) |
| Evaluation of the Interaction of Rimonabant (Antagonist of CB1 Receptor) on the Analgesic Effect of Paracetamol in Intravenous Administration [NCT00750347] | Phase 1 | 24 participants (Anticipated) | Interventional | 2008-09-30 | Completed |
| A Multicenter, Double Blind, Placebo Controlled Randomized Study of the Efficacy and Safety of Two Rimonabant/Metformin Combinations for Reducing A1C in the Treatment of Patients With Type 2 Diabetes Mellitus Who Are Not on Current Drug Therapy. [NCT00754689] | Phase 3 | 0 participants (Actual) | Interventional | 2008-09-30 | Withdrawn(stopped due to Company decision taken in light of demands by certain national health authorities) |
| Atherosclerotic Plaque Texture-Experimental and Clinical Study on the Diagnostic and Therapeutic Strategies of Atherosclerotic Plaque Vulnerability [NCT00636766] | | 300 participants (Actual) | Interventional | 2005-09-30 | Completed |
| Randomized, Multicenter, Double-Blind, Placebo-Controlled, Two-Arm Parallel Group Trial of Rimonabant 20-mg od, for Inhibition of Atherosclerosis Progression Assessed by IVUS (IntraVascular UltraSounds), in Overweight Patients With Clustering Risk Factors [NCT00124332] | Phase 3 | 839 participants (Actual) | Interventional | 2005-01-31 | Completed |
| REASURE: The Effect of Rimonabant on HbA1c in Overweight or Obese Patients With Type 2 Diabetes Not Adequately Controlled on 2 Oral Antidiabetic Agents [NCT00546325] | Phase 3 | 358 participants (Actual) | Interventional | 2007-10-31 | Completed |
| Antagonist-Elicited Cannabis Withdrawal [NCT01041170] | Phase 1 | 0 participants | Interventional | 2006-04-16 | Completed |
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, Fixed Single-dose Regimen, Multicenter Study to Assess the Efficacy and Safety of SR141716 in Obese Type 2 Diabetic Patients Inadequately Controlled With Diet and Exercise Alone [NCT00478972] | Phase 3 | 321 participants (Actual) | Interventional | 2007-04-30 | Terminated(stopped due to Company decision taken in light of demands by certain national health authorities) |
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Assess the Efficacy and Safety of SR141716 in Obese Type 2 Diabetic Patients on Monotherapy Inadequately Controlled With Oral Anti-diabetic Drug [NCT00478595] | Phase 3 | 458 participants (Actual) | Interventional | 2007-04-30 | Terminated(stopped due to Company decision taken in light of demands by certain national health authorities) |
| The Effect of Rimonabant on Energy Expenditure, Fat Metabolism and Body Composition [NCT00584389] | Phase 4 | 14 participants (Actual) | Interventional | 2007-07-31 | Terminated(stopped due to Suspension of licence for rimonabant by European Medicines Agency) |
| Single Country, Double-Blind, Randomized, 2-Arm, Parallel-Group Study, Evaluating Efficacy and Safety of Rimonabant 20 mg OD, With/Without Association of Nicotine Patch, as Aid to Smoking Cessation During 9-Week Period [NCT00458718] | Phase 3 | 755 participants (Actual) | Interventional | 2004-09-30 | Completed |
| Comparison of the Efficacy and Safety of a 20 mg/Day Oral Dose of Rimonabant Versus Placebo as an Aid to Smoking Cessation - a US, Randomized, Double-blind, 2 Arm, Placebo-controlled, Parallel-group, Fixed Dose, 12-week Study [NCT00464256] | Phase 3 | 533 participants (Actual) | Interventional | 2004-04-30 | Completed |
| A 12-month Multicentre, Randomised, Double-blind, Placebo-controlled Study With Two Parallel Groups to Assess the Effects of Rimonabant 20 mg in Patients With Abdominal Obesity and Microalbuminuria, With Type 2 Diabetes Mellitus or Dyslipidaemia With or W [NCT00458081] | Phase 3 | 174 participants (Actual) | Interventional | 2007-03-31 | Terminated(stopped due to Company decision has been taken in light of recent demands by certain national health authorities) |
| Comparison of the Efficacy and Safety of 2 Oral Doses of Rimonabant, 5 mg/Day or 20 mg/Day, Versus Placebo, as an Aid to Maintenance of Smoking Cessation (1-Year Treatment, 1-Year Follow-up) [NCT00459173] | Phase 3 | 4,850 participants (Actual) | Interventional | 2002-11-30 | Completed |
| Comparison of the Efficacy and Safety of 2 Oral Doses of Rimonabant, 5mg/Day or 20mg/Day, Versus Placebo, as an Aid to Smoking Cessation; Multiple Country, Randomized, Double-blind, 3-arm, 10-week Treatment, 40-week Follow-up [NCT00464165] | Phase 3 | 789 participants (Actual) | Interventional | 2002-11-30 | Completed |
| A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose (Rimonabant 20 mg) Multicenter Study of Long-Term Glycemic Control With Rimonabant in Treatment-naïve Patients With Type 2 Diabetes [NCT00257257] | Phase 3 | 281 participants (Actual) | Interventional | 2005-03-31 | Completed |
| A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose (Rimonabant 20mg), Multi-National, Multicentre Study of Weight-Reducing Effect and Safety of Rimonabant in Obese Patients With or Without Comorbidities [NCT00325546] | Phase 3 | 643 participants (Actual) | Interventional | 2006-04-30 | Completed |
| A Dose-Response Relationship Study of SR141716 in Obese Patients [NCT00459004] | Phase 2 | 527 participants (Actual) | Interventional | 2004-10-31 | Completed |
| A Randomized, Double-Bind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study to Assess Efficacy and Safety of Rimonabant 20 mg Versus Placebo on Weight Loss and Frequency of Binge Episodes in Obese Patients With Food Craving [NCT00481975] | Phase 3 | 289 participants (Actual) | Interventional | 2004-08-31 | Completed |
| A Randomized, Double-Blind, Two-Arm Placebo-Controlled, Parallel-Group, Multicenter Study of Rimonabant 20 mg Once Daily in the Treatment of Atherogenic Dyslipidemia in Abdominally Obese Patients [NCT00239967] | Phase 3 | 803 participants (Actual) | Interventional | 2005-05-31 | Completed |
| A Randomized Double-blind, Placebo-controlled, Parallel-group, Fixed Single-dose Regimen (SR141716 20 mg), Multicenter Study to Assess the Efficacy and Safety of SR141716 in Obese Patients With Dyslipidemia. [NCT00434096] | Phase 3 | 915 participants (Actual) | Interventional | 2007-02-28 | Terminated(stopped due to Company decision taken in light of demands by certain national health authorities) |
| A Randomized, Double-Bind, Placebo-Controlled, Parallel-Group, Fixed-Dose (20 mg/Day), 3-Month, Multicenter Study of the Energy Intake Effects and Safety of SR141716 With or Without Hypocaloric Diet in Obese Patients [NCT00481923] | Phase 3 | 156 participants (Actual) | Interventional | 2004-05-31 | Completed |
| A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study of Weight-Reducing Effect and Safety in Obese Patients With Type 2 Diabetes [NCT00029848] | Phase 3 | 1,045 participants (Actual) | Interventional | 2001-10-31 | Completed |
| Clinical Trial of the Cannabinoid CB1 Receptor Antagonist, SR141716 (Rimonabant), to Reduce Voluntary Ethanol Drinking in Healthy, Non-Treatment Seeking Individuals Who Consume Between 20 and 50 Drinks Per Week [NCT00075205] | Phase 2 | 54 participants (Actual) | Interventional | 2003-12-31 | Completed |
| A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multi-Center Study of Weight-Reducing Effect and Safety in Obese Patients With Untreated Dyslipidemias [NCT00029835] | Phase 3 | 1,033 participants (Actual) | Interventional | 2001-09-30 | Completed |
| A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study of Weight-Reducing and Prevention of Weight Regain Effects and Safety in Obese Patients With or Without Comorbidities [NCT00029861] | Phase 3 | 3,045 participants (Actual) | Interventional | 2001-08-31 | Completed |
| A Pan-European Randomized, Parallel Group, Two-arm Placebo-controlled, Double-blind Multicenter Study of Rimonabant 20mg Once Daily in the Treatment of Abdominally Obese Patients With Impaired Fasting Blood Glucose With or Without Other Comorbidities [NCT00405808] | Phase 3 | 2,666 participants (Actual) | Interventional | 2006-12-31 | Terminated(stopped due to EMEA recommendation to suspend Acomplia marketing authorisation) |
| A Randomized, Double-blind, Two Arm, Parallel, Placebo Controlled Study of Rimonabant 20 mg Effect on High Density Lipoprotein Kinetics in Patients With Abdominal Obesity and Additional Cardiometabolic Risk Factors [NCT00408148] | Phase 3 | 64 participants (Actual) | Interventional | 2006-10-31 | Terminated(stopped due to Company decision has been taken in light of recent demands by certain national health authorities) |
| A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Fixed-Dose Study Evaluating the Effect of One Dose of Rimonabant (20 mg/Day) on Glycemic Control in Type 2 Diabetic Patients Inadequately Controlled With Insulin [NCT00288236] | Phase 3 | 368 participants (Actual) | Interventional | 2006-01-31 | Completed |
| A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study of Weight-Reducing Effect and Safety of SR141716 in Obese Patients With or Without Comorbidities (RIO-Europe) [NCT00386061] | Phase 3 | 1,507 participants (Actual) | Interventional | 2001-10-31 | Completed |
| Effect of Rimonabant, a Cannabinoid Receptor 1 Antagonist on Weight Gain and Body Composition in Adults With Prader Willi Syndrome. [NCT00603109] | Phase 3 | 10 participants (Actual) | Interventional | 2007-08-31 | Terminated(stopped due to Drug side effects leading to premature stop) |
| Translational Center on the Clinical Neurobiology of Cannabis Addiction [NCT00656487] | Phase 2 | 66 participants (Actual) | Interventional | 2008-04-30 | Completed |
| Comparison of the Efficacy and Safety of 2 Oral Doses of Rimonabant, 5 mg/Day or 20 mg/Day, Versus Placebo, as an Aid to Smoking Cessation (STRATUS US, EFC4964) - A Randomized, Double-blind, 3-arm, Placebo-controlled, Parallel-group, Fixed-dose, 52-week, [NCT00358228] | Phase 3 | 787 participants (Actual) | Interventional | 2002-09-30 | Completed |
| Effects of Rimonabant on Walking Abilities in Incomplete Spinal Cord Injury: a Proof-of-concept Study [NCT05398913] | Phase 1/Phase 2 | 8 participants (Actual) | Interventional | 2021-05-12 | Completed |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |